CA-OPENGATE-CAPITAL
14.6.2019 09:02:10 CEST | Business Wire | Press release
OpenGate Capital , a global private equity firm, announced today that it has sold Omniplast BV (“Omniplast”) to a group of European investors composed of Reedcapital, Luigi M. Chiaraviglio, and Swiss Merchant Corporation. Omniplast was acquired by OpenGate in 2015 through the firm’s original, pre-fund investment in Ivy Group. Financial terms were not disclosed.
Andrew Nikou, OpenGate Capital’s founder and CEO commented, “We believe that Omniplast stands for global innovation in the fields of piping and fitting systems. I am incredibly proud of the efforts of OpenGate’s European team in the four years since acquiring Omniplast and have now fulfilled our mandate to exit the business at an ideal time. I wish the entire team at Omniplast an abundance of success under their new owners’ stewardship.”
The team at OpenGate Capital responsible for this investment and realization included: Julien Lagrèze, Partner; Sebastien Kiekert Le Moult, Partner; Marc Veillas, Managing Director; and Jonny Leppin, Senior Vice President.
Renaud Delaage, Partner at Reedcapital said, “Omniplast has a tremendous management team that will benefit greatly from the operational resources and entrepreneurial spirit that we will provide. We have a clear path to grow this business organically and through add-on acquisitions.”
Luigi M. Chiaraviglio added: “We are excited to contribute to the growth of this niche leader, whose products are exported globally, into its next phase of development.”
“We brought together investors sharing our philosophy of long-term value creation,” stated Filippo Sciorilli Borrelli, Managing Director of Swiss Merchant Corporation. Borrelli went on to say, “We are eager to start this journey.”
Luigi M. Chiaraviglio and Renaud Delaage led the transaction. Filippo Sciorilli Borrelli led the equity syndication for Swiss Merchant Corporation and played a key role in the execution.
Omniplast has earned a strong reputation and a loyal customer base within the agricultural and greenhouse sector. The business produces and distributes pressure and non-pressure PVC piping systems for the transportation of gases and fluids. Within its diverse product portfolio, Omniplast has developed five quality standards from three-layer non-pressure pipes, to irrigation and KIWA pressure pipes, to pipe-related specialties. The business is supported by forward integrated logistical solutions enabling efficient packaging and transportation. Headquartered in Veghel, The Netherlands, Omniplast has approximately 60 employees.
OpenGate Capital acquired Omniplast through its legacy, pre-fund portfolio as one of three businesses within Ivy Group. At acquisition, Omniplast had two entities in The Netherlands and Germany, which were separated in 2018 as part of a strategy to maximize each entity’s value. The German business, which specializes in PVC pipes for the residential market, was not included in the transaction.
The realization of Omniplast follows OpenGate Capital’s announcement that NAKAN, another division within Ivy Group, had been sold to Westlake Chemical Corporation in January of 2019.
About OpenGate Capital
Founded in 2005, OpenGate Capital is a global private equity firm that strives to acquire and optimize lower middle market businesses throughout North American and Europe. With a strategic international presence and a focus on corporate carve-outs and complex situations, the firm’s expertise allows it to realize a seller’s divestiture objectives while mitigating the risks associated with a business’s transition to independence. OpenGate is headquartered in Los Angeles and Paris and has a seasoned in-house team of professionals overseeing the entire lifecycle of each investment. To learn more about OpenGate, please visit www.opengatecapital.com .
About Reedcapital
Reedcapital is a private investment firm focused on the acquisition, transformation and development of lower-middle-market businesses. The firm invests in both performing and underperforming companies to create long term sustainable value. Typical investment opportunities are corporate divestitures and carve-out, complex situations and underperforming businesses. Reedcapital and its partners have been involved in over 30 transactions ranging from corporate divestitures, turnaround acquisitions, industry consolidations and other special situations investments across a wide array of industries and geographical markets. More information available on www.reedcapital.fr .
About Luigi M. Chiaraviglio
Luigi has been a private equity investor for more than 15 years, with Compass Partners in London first and Investindustrial in Milan, Lugano and New York later and has completed over 10 transactions for a value in excess of Eur 2bn including buyouts or expansion capital deals, restructurings, refinancing and exits and has been on the board of several companies in Europe and the USA. He is the Managing Director of Vista Investors, an investment firm operating through a multi-family office model, focusing on repositioning and expanding lower mid-market businesses or corporate group divisions. For more information please visit www.vista-investors.com .
About Swiss Merchant Corporation SA
Swiss Merchant Corporation(“SMC”), founded in 1990, is a corporate finance advisory boutique based in Lugano, Switzerland. SMC specializes in offering tailor made services for its clients aimed at long-term value creation. SMC’s one-stop-shop approach is designed to fulfill clients’ needs. SMC started as a private equity firm, successfully managing four investment funds from 1989 until 2015. Whilst maintaining an active role in direct investments and club deals, SMC has leveraged its experience as an advisor to its portfolio companies to focus on helping clients make informed financial decisions. More information available on www.swissmerchantcorporation.ch .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190614005028/en/
Contact:
OpenGate Media Contacts Alanna Chaffin Email: achaffin@opengatecapital.com Telephone: +1 (310) 432-7000
Mike Sitrick Sitrick & Company Email: Mike_Sitrick@sitrick.com Telephone: +1 (310) 788-2850
OpenGate Business Development Contact Joshua Adams Email: jadams@opengatecapital.com Telephone: +1 (310) 432-7000
Reedcapital Media Contact Email: media@reedcapital.fr Telephone: +33 1 72 74 10 31
Luigi M. Chiaraviglio Media Contact Email: media@vista-investors.com Telephone: +41 79 95 95 795
Swiss Merchant Corporation Media Contact Email: info@swimeco.ch Telephone: +41 91 2103568
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom